CORRECTION article

Front. Immunol., 03 April 2025

Sec. Alloimmunity and Transplantation

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1595951

Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial

  • 1. Department of Medicine, Division of Nephrology at CLS Health and Baylor College of Medicine, Houston, TX, United States

  • 2. Rare Disease Unit, Amgen Inc. (formerly Horizon Therapeutics), Thousand Oaks, CA, United States

  • 3. Division of Nephrology, Stanford School of Medicine, Stanford, CA, United States

In the published article, the reference for “The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients” was incorrectly written as “40”. It should be “14”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

gout, kidney transplant, urate, quality of life, renal function, blood pressure

Citation

Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025) Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial. Front. Immunol. 16:1595951. doi: 10.3389/fimmu.2025.1595951

Received

18 March 2025

Accepted

25 March 2025

Published

03 April 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Brad A. Marder,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics